# Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

> **NCT04790513** · PHASE3 · COMPLETED · sponsor: **LIB Therapeutics LLC** · enrollment: 204 (actual)

## Conditions studied

- Hypercholesterolemia
- Cardiovascular Diseases

## Interventions

- **BIOLOGICAL:** lerodalcibep
- **BIOLOGICAL:** evolocumab
- **BIOLOGICAL:** alirocumab

## Key facts

- **NCT ID:** NCT04790513
- **Lead sponsor:** LIB Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-22
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2023-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04790513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04790513, "Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04790513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*